Seres TherapeuticsMCRB
Market Cap: $165M
About: Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Employees: 233
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
7% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 27
6% less funds holding
Funds holding: 98 [Q1] → 92 (-6) [Q2]
11.42% less ownership
Funds ownership: 57.05% [Q1] → 45.63% (-11.42%) [Q2]
22% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 27
25% less capital invested
Capital invested by funds: $67.1M [Q1] → $50M (-$17.1M) [Q2]
33% less call options, than puts
Call options by funds: $319K | Put options by funds: $478K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Canaccord Genuity John Newman 67% 1-year accuracy 14 / 21 met price target | 826%upside $10 | Buy Maintained | 13 Sept 2024 |
Canaccord Genuity John Newman 67% 1-year accuracy 14 / 21 met price target | 826%upside $10 | Buy Maintained | 14 Aug 2024 |
Chardan Capital Keay Nakae 38% 1-year accuracy 18 / 47 met price target | 16%upside $1.25 | Buy Maintained | 14 Aug 2024 |
Financial journalist opinion
Based on 3 articles about MCRB published over the past 30 days